Cargando…
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions
BACKGROUND: Pseudobulbar affect (PBA) is associated with neurological disorders or injury affecting the brain, and characterized by frequent, uncontrollable episodes of crying and/or laughing that are exaggerated or unrelated to the patient’s emotional state. Clinical trials establishing dextrometho...
Autores principales: | Pattee, Gary L., Wymer, James P., Lomen-Hoerth, Catherine, Appel, Stanley H., Formella, Andrea E., Pope, Laura E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743597/ https://www.ncbi.nlm.nih.gov/pubmed/25062507 http://dx.doi.org/10.1185/03007995.2014.940040 |
Ejemplares similares
-
Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect
por: Schoedel, Kerri A, et al.
Publicado: (2014) -
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
por: Hammond, Flora M., et al.
Publicado: (2016) -
Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect
por: Pioro, Erik P.
Publicado: (2014) -
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
por: Hammond, Flora M., et al.
Publicado: (2016) -
Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup
por: Villeneuve, Yannick, et al.
Publicado: (2020)